
    
      Ibalizumab is to be administered to HIV-infected patients that have responded (defined as a
      minimum 0.7 log10 decline in HIV-1 viral load from TMB-202 Baseline) on the TMB-202 protocol.
      In addition to the investigator-selected Optimized Background Regimen, patient(s) will
      continue to receive the TMB-202 randomized dose of ibalizumab in open-labeled fashion (800mg
      IV every two weeks or 2000mg IV every four weeks) as per their original drug assignment for
      the TMB-202 protocol.
    
  